Rethinking pioglitazone as a cardioprotective agent: a new perspective on an overlooked drug
Since 1985, the thiazolidinedione pioglitazone has been widely used as an insulin
sensitizer drug for type 2 diabetes mellitus (T2DM). Although fluid retention was early …
sensitizer drug for type 2 diabetes mellitus (T2DM). Although fluid retention was early …
Molecular mechanisms and therapeutic implications of endothelial dysfunction in patients with heart failure
V Tsigkou, E Oikonomou, A Anastasiou… - International Journal of …, 2023 - mdpi.com
Heart failure is a complex medical syndrome that is attributed to a number of risk factors;
nevertheless, its clinical presentation is quite similar among the different etiologies. Heart …
nevertheless, its clinical presentation is quite similar among the different etiologies. Heart …
[HTML][HTML] SEDT2/METTL14-mediated m6A methylation awakening contributes to hypoxia-induced pulmonary arterial hypertension in mice
XL Zhou, FJ Huang, Y Li, H Huang, QC Wu - Aging (Albany NY), 2021 - ncbi.nlm.nih.gov
Pulmonary arterial hypertension (PAH) is a fatal disease whose molecular mechanism is
unknown. The trimethylation of lysine 36 on histone 3 (H3K36me3) catalyzed by SETD2 and …
unknown. The trimethylation of lysine 36 on histone 3 (H3K36me3) catalyzed by SETD2 and …
l‐Carnitine therapy improves right heart dysfunction through Cpt1‐dependent fatty acid oxidation
V Agrawal, AR Hemnes, NJ Shelburne… - Pulmonary …, 2022 - Wiley Online Library
Pulmonary arterial hypertension (PAH) is a fatal vasculopathy that ultimately leads to
elevated pulmonary pressure and death by right ventricular (RV) failure, which occurs in part …
elevated pulmonary pressure and death by right ventricular (RV) failure, which occurs in part …
M-type pyruvate kinase 2 (PKM2) tetramerization alleviates the progression of right ventricle failure by regulating oxidative stress and mitochondrial dynamics
L Guo, L Wang, G Qin, J Zhang, J Peng, L Li… - Journal of Translational …, 2023 - Springer
Background Right ventricle failure (RVF) is a progressive heart disease that has yet to be
fully understood at the molecular level. Elevated M-type pyruvate kinase 2 (PKM2) …
fully understood at the molecular level. Elevated M-type pyruvate kinase 2 (PKM2) …
The impact of specific pulmonary arterial hypertension therapy on cardiac fluorodeoxyglucose distribution in PET/MRI hybrid imaging–follow-up study
R Kazimierczyk, P Szumowski, SG Nekolla, LA Malek… - EJNMMI research, 2023 - Springer
Background PET/MRI hybrid imaging in pulmonary arterial hypertension (PAH) provides
important prognostic information identifying patients who might benefit from early therapy …
important prognostic information identifying patients who might benefit from early therapy …
The selective PGI2 receptor agonist selexipag ameliorates Sugen 5416/hypoxia-induced pulmonary arterial hypertension in rats
Y Honda, K Kosugi, C Fuchikami, K Kuramoto… - PLoS …, 2020 - journals.plos.org
Pulmonary arterial hypertension (PAH) is a lethal disease characterized by a progressive
increase in pulmonary artery pressure due to an increase in vessel tone and occlusion of …
increase in pulmonary artery pressure due to an increase in vessel tone and occlusion of …
Inhibition of ferroptosis reverses heart failure with preserved ejection fraction in mice
Y Xiong, X Liu, L Jiang, T Hao, Y Wang, T Li - Journal of Translational …, 2024 - Springer
Background Heart failure with preserved ejection fraction (HFpEF) accounts for
approximately 50% of heart failure cases. The molecular mechanisms by which HFpEF …
approximately 50% of heart failure cases. The molecular mechanisms by which HFpEF …
Unveiling the metabolic landscape of pulmonary hypertension: insights from metabolomics
H Ba, Y Guo, Y Jiang, Y Li, X Dai, Y Liu, X Li - Respiratory Research, 2024 - Springer
Pulmonary hypertension (PH) is regarded as cardiovascular disease with an extremely poor
prognosis, primarily due to irreversible vascular remodeling. Despite decades of research …
prognosis, primarily due to irreversible vascular remodeling. Despite decades of research …
Cardiorenal Syndrome in Right Heart Failure Due to Pulmonary Arterial Hypertension—The Right Ventricle as a Therapeutic Target to Improve Renal Function
K Ichimura, A Gross, RO Mathew, L Salman… - … Drugs and Therapy, 2024 - Springer
Cardiorenal syndrome (CRS) due to right ventricular (RV) failure is a disease entity
emerging as a key indicator of morbidity and mortality. The multifactorial aspects of CRS and …
emerging as a key indicator of morbidity and mortality. The multifactorial aspects of CRS and …